Skip to main content

Zenas BioPharma, Inc.

corporate_fare Company Profile

Zenas BioPharma, Inc.

ZBIO·NASDAQ·Life Sciences·CIK 0001953926

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing immunology-based therapies. The company specializes in immunology and inflammation (I&I) and aims to build a biopharmaceutical company in this area, leveraging the evolving understanding of autoimmune disease pathogenesis and promising immunology-based pharmacologic targets. Its business strategy involves acquiring product candidates and utilizing internal expertise and external resources. Zenas BioPharma's executive management team and industry networks are used to identify, acquire, and develop product candidates for patients with autoimmune diseases. The company's lead I&I product candidate is obexelimab, a bifunctional monoclonal antibody. Obexelimab is designed to bind to both CD19 and FcγRIIb, which are present across B cell lineage. This binding aims to inhibit the activity of cells involved in many autoimmune diseases without depleting them. Clinical data generated to date suggest that targeting B cell lineage via CD19 and FcγRIIb can inhibit B cells and has been well-tolerated. Unlike anti-CD20 or other anti-CD19 targeting agents that may deplete B cells in systemic circulation but not fully impact B cells in relevant tissue, obexelimab's mechanism of action and chronic dosing regimen are intended to broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Anti-CD20 and other anti-CD19 agents can cause prolonged depletion of circulating B cells for six months or longer, potentially increasing the risk of opportunistic infections and reducing vaccine response.

Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for ZBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ZBIO spans 10-Q, 8-K, 144, SCHEDULE 13D.

Recent high-impact activity:

  • Zenas Q3 Loss Widens to $108.9M as R&D and Milestone Costs Jump; $647.1M Cash Funds Runway Into 2029
  • Zenas Posts $647M Cash, EMA Validates Obexelimab MAA Ahead of May 2027 PDUFA
  • Zenas BioPharma Reports Positive Phase 3 INDIGO Open-Label Extension Data for Obexelimab in IgG4-RD
  • Affiliate Zebra Aggregator Files to Sell 1M Shares of Zenas BioPharma
  • Zenas BioPharma Q2 2026: $673.9M Cash, FDA BLA Accepted, CFO Transition

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$10M
Net Income
-$377.74M
Diluted EPS
-$8.44
Op. Cash Flow
-$172.33M
Free Cash Flow
-$172.35M
Operating Income
-$383.06M
Cash & Equivalents
$110.64M
Total Debt
$78.64M
Debt / Equity
0.32×
Net Margin
-37.77×
Shares Outstanding
54.49M sh
Source: 10-K · filed 2026-03-16 · accession 0001104659-26-027964

Short Interest & Short Volume

24.08 days to cover

FINRA reported short interest of 11,354,403 shares in ZBIO as of the October 30, 2026 settlement, a 9.4% decrease from the prior period — about 24.1 days to cover at its recent average daily volume. On November 20, 2026, 82.9% of ZBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,354,403 shares as of October 30, 2026
Change vs prior period▼ 9.4%
Days to cover24.08 at avg daily volume of 471,475
Daily short volume (FINRA facilities)82.9% of 149,119 shares on November 20, 2026
5-day average short volume76.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ZBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.

1 recent capital raiseATM program1 shelf registration

New $200M ATM Program Filed · Prior Program Exhausted and Terminated

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with Z →
$23 -3.56% today
52-week range · as of 2026-11-05 $13.5 – $44.6
Market cap
$1.62B
Volume
579.9K (1.1× avg)
3-mo avg 507K
Live data · 2026-11-22 07:57 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZBIO - Latest Insights

ZBIO
Nov 05, 2026, 7:19 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.46
Real-time Price: $23.00 info
Change: -$5.46 (-19%) info
Market Cap: $1.617B info
ZBIO
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $28.46
Real-time Price: $23.00 info
Change: -$5.46 (-19%) info
Market Cap: $1.617B info
ZBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.40
Real-time Price: $23.00 info
Change: -$3.40 (-13%) info
Market Cap: $1.617B info
ZBIO
Aug 19, 2026, 4:15 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $31.04
Real-time Price: $23.00 info
Change: -$8.04 (-26%) info
Market Cap: $1.617B info
ZBIO
Aug 13, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.30
Real-time Price: $23.00 info
Change: -$8.30 (-27%) info
Market Cap: $1.617B info
ZBIO
Aug 13, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.30
Real-time Price: $23.00 info
Change: -$8.30 (-27%) info
Market Cap: $1.617B info
ZBIO
Aug 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $31.30
Real-time Price: $23.00 info
Change: -$8.30 (-27%) info
Market Cap: $1.617B info
ZBIO
Jun 02, 2026, 7:06 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $17.38
Real-time Price: $23.00 info
Change: +$5.62 (+32%) info
Market Cap: $1.617B info
ZBIO
May 13, 2026, 6:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $19.16
Real-time Price: $23.00 info
Change: +$3.84 (+20%) info
Market Cap: $1.617B info
ZBIO
May 13, 2026, 6:36 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $19.16
Real-time Price: $23.00 info
Change: +$3.84 (+20%) info
Market Cap: $1.617B info
ZBIO
May 13, 2026, 6:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $19.16
Real-time Price: $23.00 info
Change: +$3.84 (+20%) info
Market Cap: $1.617B info
ZBIO
May 05, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $20.76
Real-time Price: $23.00 info
Change: +$2.24 (+11%) info
Market Cap: $1.617B info
ZBIO
Apr 29, 2026, 7:21 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $18.39
Real-time Price: $23.00 info
Change: +$4.61 (+25%) info
Market Cap: $1.617B info
ZBIO
Apr 02, 2026, 5:44 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $21.04
Real-time Price: $23.00 info
Change: +$1.96 (+9%) info
Market Cap: $1.617B info
ZBIO
Apr 01, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $20.36
Real-time Price: $23.00 info
Change: +$2.64 (+13%) info
Market Cap: $1.617B info
ZBIO
Mar 31, 2026, 5:00 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $21.90
Real-time Price: $23.00 info
Change: +$1.10 (+5%) info
Market Cap: $1.617B info
ZBIO
Mar 31, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.23
Real-time Price: $23.00 info
Change: +$2.77 (+14%) info
Market Cap: $1.617B info
ZBIO
Mar 30, 2026, 9:20 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $18.50
Real-time Price: $23.00 info
Change: +$4.50 (+24%) info
Market Cap: $1.617B info
ZBIO
Mar 30, 2026, 9:18 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $18.50
Real-time Price: $23.00 info
Change: +$4.50 (+24%) info
Market Cap: $1.617B info
ZBIO
Mar 27, 2026, 12:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $17.76
Real-time Price: $23.00 info
Change: +$5.24 (+30%) info
Market Cap: $1.617B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets